Opyl executive director demonstrates confidence in biotechnology strategy with on-market purchase

Opyl Ltd executive director Damon Rasheed has demonstrated confidence in the company’s biotechnology strategy with the purchase of shares in an on-market transaction.

“It’s sincerely encouraging that we can optimise the continued investment in our AI-based platforms and tools, while at the same time keep cash flows stable as we lean into and open up current and emerging revenue opportunities.” – CEO Michelle Gallaher.

This is only an excerpt. The original was written by Proactive Investors and can be found here.